Ebselen protects both gray and white matter in a rodent model of focal cerebral ischemia

Stroke

Volumn 32, Issue 9, 2001, Pages 2149-2156

  Imai, H ^a   Masayasu, H ^b   Dewar, D ^a   Graham, D I ^a   Macrae, I Mhairi ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b DAIICHI SANKYO CO   (Japan)

Author keywords

Antioxidants; Free radicals; Oxidative stress; Rats; Stroke, experimental; White matter

Indexed keywords

ANTIOXIDANT; EBSELEN; FREE RADICAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXONAL INJURY; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFICACY; GRAY MATTER; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; STROKE; WHITE MATTER;

EID: 0034821411     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/hs0901.095725     Document Type: Article

References (42)

1. Pathobiology of ischaemic stroke: An integrated view
2. Role of oxidants in ischemic brain damage
3. The anti-inflammatory activity of ebselen but not thiols in experimental alveolitis and bronchiolitis
4. The effect of ebselen on polymorphonuclear leukocyte and lymphocyte migration to inflammatory reactions in rats
5. A novel biologically active selenoorganic compound-I: Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen)
6. Kinetic mechanism and substrate specificity of glutathione peroxidase activity of ebselen (PZ51)
7. The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat
8. Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion
9. Ebselen in acute ischemic stroke: A placebo-controlled, double-blind clinical trial
10. Ebselen in acute middle cerebral artery occlusion: A placebo-controlled, double-blind clinical trial
11. Neuroprotective efficacy of an intravenous formulation of ebselen in a rodent model of focal ischaemia
12. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing?
13. The changing landscape of ischaemic brain injury mechanism
14. Drug development for stroke: Importance of protecting cerebral white matter
15. White matter ischaemia
16. The N-methyl-D-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats
17. NMDA receptor blockade fails to alter axonal injury in focal cerebral ischaemia
18. Quantitative assessment of ischemic pathology in axons, oligodendrocytes, and neurons: Attenuation of damage after transient ischaemia
19. Experimental studies of ischemic brain edema, I: A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area
20. Functional assessments in mice and rats after focal stroke
21. Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia
22. Rapid alteration of tau in oligodendrocytes after focal ischemic injury in the rat: Involvement of free radicals
23. Oxidative damage and breakage of DNA in rat brain after transient MCA occlusion
24. The lipid peroxidation by-product 4-hydroxynonenal is toxic to axons and oligodendrocytes
25. Tau protein is altered by focal cerebral ischaemia in the rat: An immunohistochemical and immunoblotting study
26. Hypoxia and vascular disorders of the central nervous system
27. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischaemia
28. Both NMDA and non-NMDA subtypes of glutamate receptors are concentrated at synapses on cerebral cortical neurones in culture
29. Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity
30. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter
31. The severity of ischemia and extent of axonal pathology in white matter after middle cerebral artery occlusion in the rat
32. Ebselen: Prospective therapy for cerebral ischaemia
33. Ebselen as a glutathione peroxidase mimic and as a scavenger of peroxynitrite
34. Strong inhibition of mammalian lipoxygenases by the antiinflammatory seleno-organic compound ebselen in the absence of glutathione
35. Preferential inhibition of inducible nitric oxide synthase by ebselen
36. Studies on the anti-inflammatory activity of ebselen: Ebselen interferes with granulocyte oxidative burst by dual inhibition of NADPH oxidase and protein kinase C?
37. Ebselen is a specific inhibitor of LTB4-mediated migration of human neutrophils
38. Selenoorganic compound, ebselen, inhibits nitric oxide and tumor necrosis factor-alpha production by the modulation of jun-N-terminal kinase and the NF-kappa-b signaling pathway in rat Kupffer cells
39. 4-Hydroxynonenal increases neuronal susceptibility to oxidative stress
40. 4-Hydroxynonenal induces oxidative stress and death of cultured spinal cord neurons
41. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis